Comments
Loading...

Invesco Biotechnology & Genome ETF Stock Price, Quotes and Forecasts

PBEARCA
Logo brought to you by Benzinga Data
$61.08
-0.03-0.05%
At close: -
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Sector
Healthcare
Region
US
AUM
219.40M
Fund Score

Invesco Biotechnology & Genome ETF Price, Quotes and Forecasts | ARCA:PBE | Benzinga

Explore Invesco Biotechnology & Genome ETF stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for PBE.

Open$60.15
High$61.09
52 Wk High$72.84
AUM219.40M
Dividend$0.06
Ex-Div DateJun 24, 2024
Volume7.38K
Market Cap$25.81B
Mgmt Fee0.5%
P/E Ratio23.84
Prev. Close$61.11
Low$60.15
52 Wk Low$54.52
Shares Out4.04M
Yield0.09%
Div. FreqQuarterly
Avg. Volume Daily12.08K
Beta0.81
Avg. Expense Ratio0.58%
P/B Ratio4.19

FAQ

Q

How do I buy Invesco Biotechnology & Genome ETF (PBE) stock?

A

You can purchase shares of Invesco Biotechnology & Genome ETF (ARCA:PBE) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Invesco Biotechnology & Genome ETF (PBE) competitors?

A

There are no as such competitors for Invesco Biotechnology & Genome ETF.

Q

What is the forecast, or price target, for Invesco Biotechnology & Genome ETF (PBE) stock?

A

There is no analysis for Invesco Biotechnology & Genome ETF to provide a consensus price target.

Q

What is the current price for Invesco Biotechnology & Genome ETF (PBE)?

A

The stock price for Invesco Biotechnology & Genome ETF (ARCA: PBE) is $61.0801 last updated April 25, 2025 at 8:00 PM EDT.

Q

Does Invesco Biotechnology & Genome ETF (PBE) pay a dividend?

A

A quarterly cash dividend of 0.00 per share of Class A Common Stock. The quarterly cash dividend was payable on September 28, 2018 to stockholders of record on September 24, 2018.

Q

When is Invesco Biotechnology & Genome ETF (ARCA:PBE) reporting earnings?

A

Invesco Biotechnology & Genome ETF does not have any upcoming earnings scheduled.

Q

Is Invesco Biotechnology & Genome ETF (PBE) going to split?

A

There is no upcoming split for Invesco Biotechnology & Genome ETF.

Open$60.15
High$61.09
52 Wk High$72.84
AUM219.40M
Dividend$0.06
Ex-Div DateJun 24, 2024
Volume7.38K
Market Cap$25.81B
Mgmt Fee0.5%
P/E Ratio23.84
Prev. Close$61.11
Low$60.15
52 Wk Low$54.52
Shares Out4.04M
Yield0.09%
Div. FreqQuarterly
Avg. Volume Daily12.08K
Beta0.81
Avg. Expense Ratio0.58%
P/B Ratio4.19
About Invesco Capital Management LLC
Sector
N/A
Industry
N/A
Got Questions? Ask
How is PBE's ROE trending?
How is the earnings season affecting PBE?
What is PBE's all-time high price?
What is PBE's all-time low price?
What is PBE's P/S ratio?
ETF Details
SectorHealthcare
CategoryMid Performer-Mid Growth
Investment StyleMid Cap Growth
Fund InceptionJun 23, 2005
Managers
Tony Seisser
Michael Jeanette
Peter Hubbard
Pratik Doshi
DefinitionMost of the stocks in this equity fund have average financial performance and average growth potential
Investment Policy
The Fund generally will invest at least 90% of its total assets in securities that comprise the Underlying Index. The Underlying Index is composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, and are companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research.
Top ETF Holdings
SymbolNameShare %
GILDGilead Sciences Inc5.27%
ILMNIllumina, Inc.4.35%
INCYIncyte Corp.5.20%
BMRNBiomarin Pharmaceutica...5.09%
VRTXVertex Pharmaceuticals...5.05%
AMGNAmgen Inc5.18%
REGNRegeneron Pharmaceutic...4.60%
NBIXNeurocrine Biosciences...5.01%
IONSIonis Pharmaceuticals ...3.24%
HALOHalozyme Therapeutics ...3.51%
NTRANatera Inc4.76%
BIIBBiogen Inc5.00%
UTHRUnited Therapeutics Co...4.52%
AXSMAxsome Therapeutics, I...3.71%
DURpi International Hold...3.60%
PTGXProtagonist Therapeuti...3.94%
TGTXTg Therapeutics Inc3.86%